Metabolism and excretion of atorvastatin in rats and dogs

Drug Metabolism and Disposition

Volumn 27, Issue 8, 1999, Pages 916-923

  Black, Ann E ^a   Hayes, Roger N ^a   Roth, Bruce D ^a   Woo, Peter ^a   Woolf, Thomas F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ARTICLE; BILE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INHIBITION; FECES; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERCHOLESTEROLEMIA; MALE; MASS SPECTROMETRY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOACTIVITY; RAT; URINALYSIS;

ANIMALS; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FEMALE; GLUCURONIDASE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES; RATS; SPECIES SPECIFICITY; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT;

EID: 0032791745     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn SL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ and Black DM (1996) Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc 275:128-133.
2. Baumann KL, Butler DE, Deering CF, Mennen KE, Millar A, Nanninga TN, Palmer CW and Roth BD (1992) The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 33:2283-2284.
3. Black A, Sinz MW, Hayes RN and Woolf TW (1998) Metabolism and excretion studies in mouse following single and multiple oral doses of the HMG CoA reductase inhibitor Atorvastatin. Drug Metab Dispos 26:755-763.
4. Bocan TMA, Ferguson E, McNally W, Uhlendorf PD, Bak Mueller S, DeHart P, Sliskovic DR, Roth BD, Krause BR and Newton RS (1992) Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor. CI-981: Comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1123:133-144.
5. Desager J-P and Horsmans Y (1996) Clinical pharmacokinetics of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors. Clin Phamacokinet 5:348-371.
6. Duggan DE, Chen I-W, Bayne WF, Halpin RA, Duncan CA, Schwatz MS, Stubbs RJ and Vickers S (1989) The physiological disposition of lovastatin. Drug Metab Dispos 17:166-173.
7. Duggan DE and Vickers S (1990) Physiological Disposiation of HMG-CoA-Reductase Inhibitors. Drug Metab Rev 22:333-362.
8. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas LP, Hunninghake DB and Duggan DE (1993) Biotransformation of lovastatin V: Species differences in in vivo metabolite profiles in mouse, rat, dog, and human. Drug Metab Dispos 21:1003-1011.
9. Hayes RN, Black A, Hicks JL and Woolf TF (1994) Identification of metabolites of CI-981 atorvastatin) in rat bile using tandem mass spectrometry and a stable isotope tracer (Abstract). 42nd ASMS Conference on Mass Spectroscopy and Allied Topics; 1994 May 29-Jun 3, Chicago, IL. Elsevier Science Inc. 53.
10. Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E and Tanaka M (1992) Disposition and metabolism of pravastatin sodium in rats, dogs, and monkeys. Eur J Metab and Pharmacokinet 17:103-133.
11. 14C atorvastatin in patients with T-tube drainage. Proc Aust Soc Clin Exp Pharmacol Toxicol 3:153.
12. Michniewicz BM, Black AE, Sinz MW and Woolf TF (1994) In vitro and in vivo metabolism of atorvastatin (C1-981) (Abstract). ISSX Proc 6:93.
13. Nawrocki J, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber HE and Black DM (1995) Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterio Thromb Vasc Bio 15:678-682.
14. Roth BD, Blankley CJ, Chucholowski AW, Ferguson E, Hoefle ML, Ortwine DL, Newton RS, Sekerke CS, Sliskovic DR, Stratton CD and Wilson MW (1991) Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[(1H-pyrrol-1-y1)ethyl)-2H-pyran-2-one inhibitors of HMC-CoA reductase. 2. Effects of introducing substituents as positions three and four of the pyrrole nucleus. J Med Chem 34:357-366.
15. Shum YY, Huang H, Walter G, Black AE, Sekerke CS, Homan R, Newton RS, Nordblom GD, Wright DS, Chang T and Whitfield LR (1993) Development and validation of an enzyme inhibition assay for quantitation of CI-981 in human plasma. Pharm Res 10:S-415.
16. 3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. Biopharm Drug Dispos 16:211-219.
17. Vickers S, Duncan SA, Chen I-W, Rosegay A and Duggan DE (1990) Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18:138-145.
18. Whitfield LR, Cilla DD Jr, Posvar EL, Sedman AJ and Gibson DL (1993) Single-and multiple-dose pharmacokinetics of CI-981, a potent HMG-CoA reductase inhibitor. Pharm Res 10:S-340.